Senseonics Holdings, Inc. SENS
We take great care to ensure that the data presented and summarized in this overview for Senseonics Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SENS
View all-
Vanguard Group Inc Valley Forge, PA23.5MShares$21.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.32MShares$7.66 Million0.0% of portfolio
-
Masters Capital Management LLC Atlanta, GA7MShares$6.44 Million0.12% of portfolio
-
Geode Capital Management, LLC Boston, MA5.84MShares$5.37 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA3.34MShares$3.07 Million0.0% of portfolio
-
State Street Corp Boston, MA1.89MShares$1.74 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.07MShares$988,5570.0% of portfolio
-
Gmt Capital Corp Atlanta, GA729KShares$671,0260.01% of portfolio
-
Pathstone Family Office, LLC Englewood, NJ511KShares$470,1200.0% of portfolio
-
Pathstone Holdings, LLC Englewood, NJ510KShares$469,2000.0% of portfolio
Latest Institutional Activity in SENS
Top Purchases
Top Sells
About SENS
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Insider Transactions at SENS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 02
2025
|
Edward Fiorentino |
BUY
Grant, award, or other acquisition
|
Direct |
29,862
+2.46%
|
$0
$0.47 P/Share
|
|
Jan 02
2025
|
Douglas A Roeder |
BUY
Grant, award, or other acquisition
|
Direct |
31,183
+2.04%
|
$0
$0.47 P/Share
|
|
Jan 02
2025
|
Edelman Steven |
BUY
Grant, award, or other acquisition
|
Direct |
27,219
+2.4%
|
$0
$0.47 P/Share
|
|
Jan 02
2025
|
Douglas S Prince |
BUY
Grant, award, or other acquisition
|
Direct |
17,177
+1.78%
|
$0
$0.47 P/Share
|
|
Dec 13
2024
|
Douglas A Roeder |
BUY
Open market or private purchase
|
Direct |
25,000
+1.74%
|
$0
$0.5 P/Share
|
|
Dec 12
2024
|
Douglas A Roeder |
BUY
Open market or private purchase
|
Direct |
300,000
+17.77%
|
$0
$0.41 P/Share
|
|
Dec 12
2024
|
Frederick T. Sullivan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
124,933
+4.8%
|
$0
$0.38 P/Share
|
|
Dec 10
2024
|
Timothy T Goodnow President and CEO |
BUY
Open market or private purchase
|
Direct |
315,000
+2.71%
|
$0
$0.31 P/Share
|
|
Nov 15
2024
|
Timothy T Goodnow President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
632,166
-5.44%
|
$0
$0.28 P/Share
|
|
Nov 15
2024
|
Kenneth L Horton GC & Corp. Development Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
187,665
-6.48%
|
$0
$0.28 P/Share
|
|
Nov 15
2024
|
Mukul Jain Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
282,546
-5.63%
|
$0
$0.28 P/Share
|
|
Nov 15
2024
|
Francine Kaufman Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
118,645
-5.02%
|
$0
$0.28 P/Share
|
|
Nov 15
2024
|
Frederick T. Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
181,627
-7.16%
|
$0
$0.28 P/Share
|
|
Oct 01
2024
|
Edward Fiorentino |
BUY
Grant, award, or other acquisition
|
Direct |
41,901
+3.51%
|
$0
$0.34 P/Share
|
|
Oct 01
2024
|
Edelman Steven |
BUY
Grant, award, or other acquisition
|
Direct |
38,193
+3.42%
|
$0
$0.34 P/Share
|
|
Oct 01
2024
|
Douglas S Prince |
BUY
Grant, award, or other acquisition
|
Direct |
24,102
+2.53%
|
$0
$0.34 P/Share
|
|
Oct 01
2024
|
Douglas A Roeder |
BUY
Grant, award, or other acquisition
|
Direct |
43,755
+3.87%
|
$0
$0.34 P/Share
|
|
Jul 01
2024
|
Edelman Steven |
BUY
Grant, award, or other acquisition
|
Direct |
32,529
+3.03%
|
$0
$0.4 P/Share
|
|
Jul 01
2024
|
Edward Fiorentino |
BUY
Grant, award, or other acquisition
|
Direct |
35,687
+3.11%
|
$0
$0.4 P/Share
|
|
Jul 01
2024
|
Douglas S Prince |
BUY
Grant, award, or other acquisition
|
Direct |
20,528
+2.22%
|
$0
$0.4 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 12.3M shares |
|---|---|
| Open market or private purchase | 765K shares |
| Payment of exercise price or tax liability | 2.81M shares |
|---|